Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Dabrafenib and/or Trametinib Rollover Study |
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | Phase4 | Spain United States |
NCT03340506 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | South Korea | NCT05943522 | |
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
Lupus Nephritis | Phase2 | China France Germany India Malaysia Philippines Portugal Puerto Rico Singapore Spain Turkey (Türkiye) United States View all |
NCT05268289 |
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population |
Hidradenitis Suppurativa | Italy | NCT07543419 | |
REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria |
Paroxysmal Nocturnal Hemoglobinuria (PNH) | Italy | NCT07229235 | |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | South Korea Switzerland United States |
NCT07357727 |
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction |
Heart Failure With Reduced Ejection Fraction | Phase1 | United States | NCT07465653 |
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction |
Plaque, Atherosclerotic | Phase4 | China | NCT06372925 |
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy |
Secondary Malignancies of T-cell Origin | Japan | NCT07378969 | |
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) |
Cardiovascular Disease and Lipoprotein(a) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria China Colombia Czechia Denmark France Germany Greece Hong Kong Hungary India Israel Italy Japan Netherlands Poland Portugal Puerto Rico Romania Russia Slovakia South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT07517263 |